Mycophenolate Mofetil Capsules

The mechanism of action of this product has the following specificity: (1) It selectively inhibits the classical guanine synthesis pathway of lymphocytes and has no toxic effects on non-lymphocytes and/or organs; (2) It directly inhibits B cell proliferation, while cyclosporine has no effect on inhibiting antibody formation; (3) It effectively reduces the activity of adhesion molecules, inhibits the proliferation of vascular smooth muscle cells, and can prevent and treat vascular rejection reactions and reduce the occurrence of chronic rejection reactions.

This product is mycophenolate mofetil.

This product is an orange and blue two-color capsule, and the contents are white or off-white lumps or (and) powder.

This product is used to prevent acute organ rejection and treat refractory rejection after allogeneic renal transplantation. This product should be used simultaneously with cyclosporine and corticosteroids.

Dosage for preventing renal transplant rejection: The first dose of this product should be taken orally within 72 hours after transplantation. For renal transplant patients, 1 gram each time, twice a day (daily dose of 2 grams) is recommended. Although 1.5 grams each time, twice a day (daily dose of 3 grams) has been used in clinical trials and is safe and effective, it has no advantage in effectiveness. Patients who receive 2 grams of this product per day have better overall safety than patients who receive 3 grams. This product should be used simultaneously with standard doses of cyclosporine and corticosteroids. Dosage for treating refractory renal transplant rejection In clinical practice, the treatment and maintenance dose for refractory rejection is 1.5 grams per day, twice a day (daily dose of 3 grams). Therefore, a dose of 3 grams per day is recommended for clinical use. This product should be used simultaneously with standard doses of cyclosporine and corticosteroids.

The characteristics of adverse reactions associated with the use of immunosuppressants are often difficult to establish, partly because of the presence of underlying diseases and partly because of the combined use of multiple other drugs. 1. During the prophylactic rejection treatment of renal, heart and liver transplants, the main adverse reactions of using CellCept in combination with cyclosporine and corticosteroids include diarrhea, leukopenia, sepsis and vomiting, and there are signs of a high frequency of certain types of infections, such as infections with opportunistic pathogens. 2. Malignancies: Patients receiving immunosuppressive regimens, including patients with concomitant drugs, and patients receiving CellCept as part of their immunosuppression have an increased risk of developing lymphomas and malignancies, especially of the skin. 3. Opportunistic pathogen infections: All transplant patients

Allergic reactions to Cellcept have been found. Therefore, patients who have allergic reactions to MMF or MPA should not use Cellcept.

Precautions for children: 1. Based on the pharmacokinetic and safety data of children after kidney transplantation, the recommended dose is 600 mg/m2 bid (up to 1 g bid) of mycophenolate mofetil taken orally. 2. The safety and effectiveness of pediatric patients receiving heart or liver allogeneic transplants have not been determined. Precautions for pregnancy and lactation: Animal experiments have found that this drug may cause fetal malformations. This drug should be taken only after a negative pregnancy test. During the use of this drug, effective contraceptive measures should be taken. MMF may have potentially serious side effects on breastfeeding infants. Precautions for the elderly: Clinical trials of mycophenolate mofetil did not include enough elderly people aged 65 or above, and it cannot be determined whether the effects on the elderly are different from those on young people. Other reported clinical experiences have not determined the difference in effects between the elderly and the young. In general, the dose selection for the elderly should be cautious because more elderly people have decreased kidney, heart and liver function and more concomitant use of other drugs. Compared with young people, adverse reactions may be more common in the elderly.

Drug interactions may occur if used with other drugs. Please consult your doctor or pharmacist for details.

Keep away from light and store in sealed container.

0.25g

36 months

Hunan Warrant Pharmaceutical Co., Ltd.

• Founded in:

  2001-04-30

• Address:

  Hunan Liuyang Biomedicine Park

• Tax NO.:

  914301007279773228

• Registered Funds:

  93.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view